Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Fred Khosravi and AccessClosure (C)
Hamermesh, Richard G.; Barley, LaurenCaso HBS-814074-EIniciativa emprendedoraOn September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the company. The future looked bright for AccessClosure as 2013 drew to a close. The company expected 2014 revenues of more than $100 million with a gross margin of greater than 70%. It wa...Desde 5,74 €
-
Whose Money Is It Anyway (C)
Narayanan, V.G.; Hamermesh, Richard G.; Gordon, RachelCaso HBS-810031-EContabilidad y controlThe case describes how the Brigham and Women's Physicians Organization and its corporate parent resolved the issue of how the disputed funds would be distributed and used.Desde 5,74 €
-
Whose Money Is It Anyway (A), (B), and (C), Teaching Note
Hamermesh, Richard G.; Narayanan, V.G.; Gordon, RachelNota del Instructor HBS-111128-EContabilidad y controlTeaching Note for 810-008, 810-013, and 810-031.Desde 0,00 €
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCaso HBS-813037-EIniciativa emprendedoraThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Desde 8,20 €
-
How to Pay for Health Care
Porter, Michael E.; Kaplan, Robert S.Artículo HBS-R1607G-ELiderazgo y Dirección de personasThe United States stands at a crossroads in how to pay for health care. Fee for service, the dominant payment model in the U.S. and many other countries, is now widely recognized as perhaps the single biggest obstacle to improving health care delivery. A battle is currently raging, outside of the public eye, between the advocates of two radically different payment approaches: capitation and bundled payments. The stakes are high, and the outcome w...Desde 8,20 €
-
How to Solve the Cost Crisis in Health Care
Kaplan, Robert S.; Porter, Michael E.Artículo HBS-R1109B-ELiderazgo y Dirección de personasU.S. health care costs currently exceed 17% of GDP and continue to rise. One fundamental reason that providers are unable to reverse the trend is that they don't understand what it costs to deliver patient care or how those costs compare with outcomes. To put it bluntly, few health care providers measure the actual costs for treating a given patient with a given medical condition over a full cycle of care, or compare the costs they incur with the...Desde 8,20 €
-
For the Last Time: Stock Options Are an Expense (Spanish version)
Bodie, Zvi; Kaplan, Robert S.; Merton, Robert C.Artículo HBS-R0303DContabilidad y controlShould stock options be recorded as an expense on a company's income statement and balance sheet, or should they remain where they are, relegated to footnotes? The authors believe the case for expensing options is overwhelming. In this article, Nobel laureate Robert Merton, one of the inventors of the Black-Scholes option-pricing model; his co-author on the classic textbook Finance, Zvi Bodie; and Robert Kaplan, creator of the Balanced Scorecard,...Desde 8,20 €
-
How to Solve the Cost Crisis in Health Care (Spanish version)
Kaplan, Robert S.; Porter, Michael E.Artículo HBS-R1109BLiderazgo y Dirección de personasU.S. health care costs currently exceed 17% of GDP and continue to rise. One fundamental reason that providers are unable to reverse the trend is that they don't understand what it costs to deliver patient care or how those costs compare with outcomes. To put it bluntly, few health care providers measure the actual costs for treating a given patient with a given medical condition over a full cycle of care, or compare the costs they incur with the...Desde 8,20 €
-
Medtronic: Navigating a Shifting Healthcare Landscape
Kaplan, Robert S.; Porter, Michael E.; Feeley, Thomas W; Hernandez, AleeCaso HBS-718471-EDirección estratégicaMedtronic is adapting its strategy to changes in health care competition and payments. It has decided to develop new relationships with payers, hospitals, and physicians to become more accountable for patient outcomes and total costs. The case describes new forms of partnerships for therapy optimization, management of acute care episodes, and management of chronic care patients.Desde 8,20 €
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Caso HBS-302S36Conocimiento y comunicaciónDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Desde 8,20 €